- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 417/04
Total number of patents in this class: 4110
10-year publication summary
|
266
|
314
|
345
|
297
|
284
|
243
|
270
|
224
|
208
|
114
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4729 |
90 |
| Novartis AG | 10263 |
52 |
| Merck Sharp & Dohme LLC | 3735 |
49 |
| Bayer AG | 3495 |
46 |
| F. Hoffmann-La Roche AG | 7836 |
43 |
| Janssen Pharmaceutica N.V. | 3171 |
43 |
| Hoffmann-La Roche Inc. | 3783 |
42 |
| Merck Patent GmbH | 5725 |
42 |
| VALO Health, Inc. | 193 |
42 |
| Boehringer Ingelheim International GmbH | 4493 |
41 |
| Vertex Pharmaceuticals Incorporated | 1584 |
39 |
| Rigel Pharmaceuticals, Inc. | 507 |
35 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
33 |
| BASF SE | 21303 |
32 |
| Amgen Inc. | 4425 |
32 |
| Abbvie Inc. | 1836 |
30 |
| The Regents of the University of California | 20720 |
28 |
| Syngenta Participations AG | 1527 |
28 |
| Takeda Pharmaceutical Company Limited | 2715 |
28 |
| Bayer Cropscience AG | 1846 |
27 |
| Other owners | 3308 |